Live from BIO: Day three in review

For real innovation, look beyond science
by Maureen Martino
The biotech and pharmaceutical industries are in the process of reevaluating their approach to R&D to address a myriad of economic and social realities. But if there's one thing that's clear, it's that companies are still capable of good science. Yes, developers are having a tough time moving that science from the bench to the clinic and ultimately to approval, but scientific discovery isn't the problem. Story

E&Y: Biotechs have to do more with less
by Liz Jones Hollis
A panel of biotech leaders, including Sanofi CEO Chris Viehbacher, spoke at a panel Tuesday at the BIO International Convention to discuss the Ernst & Young 25th Annual Biotechnology Industry Report. As E&Y notes, scarce funding means companies and their investors have had to realign strategies through restructuring or partnering with larger companies earlier. And the situation isn't going to change any time soon. Article

Making deals with Big Pharma
by Erica Teichert
As the number of venture capital deals grows smaller and the patent cliff looms, Big Pharma is looking for quality deals with small biotechs, according to a panel at the BIO International Conference, and the industry is focusing first on the best science. Article

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.